Many developed-country health-care firms have deep roots in emerging markets and can be a good way to gain exposure, says Morningstar's Damien Conover .
Five stats from the market and the stories behind them. This week: content kings, patent cliffs, and 30,000 head to Omaha.
Dave Ricks, head of Lilly's Bio-Medicines group, discusses the pharma giant's competitive advantages with Morningstar's Damien Conover .
Pharmaceutical firms' lower-than-historical valuations and high-margin, patent-protected products are positive signs for investors seeking more yield.
Pharmaceutical firms have adapted to their patent cliffs better than investors expected, and solid pricing power and improving pipelines are allowing them to push through macro headwinds.
Obamacare will benefit some sectors more than others, but poor economy and pricing pressures are the biggest challenges most health-care firms must face.
Morningstar hosted its second ETF Invest Conference Sept. 22-23 in Chicago.
Two veteran investors discuss the winners and losers of reform and where they're looking for future growth.
Things look grim, but investors who can bear it could benefit.
Berkshire's portfolio can give some guidance to weary investors.